Gene expression profile of colon cancer cell lines treated with SN-38

Chemotherapy

Volumn 56, Issue 1, 2010, Pages 17-25

  Wallin, A ^a   Francis, P ^b   Nilbert, M ^b,c   Svanvik, J ^a   Sun, X F ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Colorectal cancer; Gene expression; KM12C; KM12L4a; KM12SM; SN 38

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE ARREST; CELL DIFFERENTIATION; COLON CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN TRANSPORT; RNA PROCESSING; SIGNAL TRANSDUCTION; UPREGULATION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL LINE, TUMOR; COLONIC NEOPLASMS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 77950541479     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000287353     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA: a cancer journal for clinicians 2008; 58: 71-96.
2. Cancer Incidence in Sweden 2006. Statistics - Health and Diseases, vol 16. Stockholm, Socialstyrelsen (The National Board of Health and Welfare), 2007.
3. Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C, Herait P: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-1418. (Pubitemid 28510874)
4. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques C: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407-1412. (Pubitemid 28510873)
5. Idelevich E, Greif F, Mavor E, Miller R, Kashtan H, Susmalian S, Ariche A, Brenner B, Baruch NB, Dinerman M, Shani A: Phase ii study of uft with leucovorin plus hepatic arterial infusion with irinotecan, 5-fluorouracil and leucovorin for non-resectable liver metastases of colorectal cancer. Chemotherapy 2009; 55: 76-82.
6. Gibbs P, Brown TJ, Ng R, Jennens R, Cinc E, Pho M, Michael M, Fox RM: A pilot human evaluation of a formulation of irinotecan and hyaluronic acid in 5-fluorouracil-refractory metastatic colorectal cancer patients. Chemotherapy 2009; 55: 49-59.
7. Tsavaris N, Kosmas C, Skopelitis H, Papadoniou N, Polyzos A, Zografos G, Adoniou E, Gryniatsos J, Felekouras E, Zacharakis M, Sigala F, Bacoyiannis C, Papastratis G, Papalambros E: Sequential administration of 5-fluorouracil (5fu)/leucovorin (lv) followed by irinotecan (cpt-11) at relapse versus cpt-11 followed by 5-FU/LV in advanced colorectal carcinoma: a phase III randomized study. Chemotherapy 2007; 53: 282-291.
8. Hertzberg RP, Caranfa MJ, Holden KG, Jakas DR, Gallagher G, Mattern MR, Mong SM, Bartus JO, Johnson RK, Kingsbury WD: Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 1989; 32: 715-720.
9. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K: Intracellular roles of sn-38, a metabolite of the camptothecin derivative cpt-11, in the antitumor effect of cpt-11. Cancer Res 1991; 51: 4187-4191.
10. Hsiang YH, Lihou MG, Liu LF: Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989; 49: 5077-5082.
11. Zamboni WC, Stewart CF, Cheshire PJ, Richmond LB, Hanna SK, Luo X, Poquette C, McGovren JP, Houghton JA, Houghton PJ: Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models. Clin Cancer Res 1998; 4: 743-753.
12. Wallin A, Svanvik J, Holmlund B, Ferreud L, Sun XF: Anticancer effect of SN-38 on colon cancer cell lines with different metastatic potential. Oncol Rep 2008; 20: 1493-1498.
13. Saal LH, Troein C, Vallon-Christersson J, Gruvberger S, Borg A, Peterson C: BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data. Genome Biology 2002; 3:SOFTWARE0003.
14. Yang YH, Dudoit S, Luu P, Lin DM, Peng V, Ngai J, Speed TP: Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 2002; 30: e15.
15. Chen Y, Kamat V, Dougherty ER, Bittner ML, Meltzer PS, Trent JM: Ratio statistics of gene expression levels and applications to microarray data analysis. Bioinformatics (Oxford, England) 2002; 18: 1207-1215.
16. Fernebro J, Francis P, Eden P, Borg A, Panagopoulos I, Mertens F, Vallon-Christersson J, Akerman M, Rydholm A, Bauer HC, Mandahl N, Nilbert M: Gene expression profiles relate to ss18/ssx fusion type in synovial sarcoma. Int J Cancer 2006; 118: 1165-1172.
17. Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, Braisted J, Klapa M, Currier T, Thiagarajan M, Sturn A, Snuffin M, Rezantsev A, Popov D, Ryltsov A, Kostukovich E, Borisovsky I, Liu Z, Vinsavich A, Trush V, Quackenbush J: TM4: a free, open-source system for microarray data management and analysis. BioTechniques 2003; 34: 374-378.
18. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES: Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999; 286: 531-537.
19. Hosack DA, Dennis G Jr, Sherman BT, Lane HC, Lempicki RA: Identifying biological themes within lists of genes with ease. Genome Biol 2003; 4:R70.
20. Liu W, Quinto I, Chen X, Palmieri C, Rabin RL, Schwartz OM, Nelson DL, Scala G: Direct inhibition of Bruton's tyrosine kinase by IBtk, a Btk-binding protein. Nat Immunol 2001; 2: 939-946.
21. Sun XF, Ekberg H, Zhang H, Carstensen JM, Nordenskjold B: Overexpression of ras is an independent prognostic factor in colorectal adenocarcinoma. APMIS 1998; 106: 657-664.
22. Altieri DC: Survivin, cancer networks and pathway-directed drug discovery. Nat Rev 2008; 8: 61-70.
23. Jiang K, Delarue FL, Sebti SM: EGFR, ErbB2 and Ras but not Src suppress RhoB expression while ectopic expression of RhoB antagonizes oncogene-mediated transformation. Oncogene 2004; 23: 1136-1145.
24. Sebens Muerkoster S, Rausch AV, Isberner A, Minkenberg J, Blaszczuk E, Witt M, Folsch UR, Schmitz F, Schafer H, Arlt A: The apoptosis- inducing effect of gastrin on colorectal cancer cells relates to an increased IEX-1 expression mediating NF-kappa B inhibition. Oncogene 2008; 27: 1122-1134.
25. Jacobs MD, Harrison SC: Structure of an IkappaBalpha/NF-kappaB complex. Cell 1998; 95: 749-758.
26. Hayward RL, Macpherson JS, Cummings J, Monia BP, Smyth JF, Jodrell DI: Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity. Clin Cancer Res 2003; 9: 2856-2865.
27. Souza V, Dong YB, Zhou HS, Zacharias W, McMasters KM: Sw-620 cells treated with topoisomerase I inhibitor Sn-38: gene expression profiling. J Transl Med 2005; 3: 44.
28. Guo B, Cao S, Toth K, Azrak RG, Rustum YM: Overexpression of Bax enhances antitumor activity of chemotherapeutic agents in human head and neck squamous cell carcinoma. Clin Cancer Res 2000; 6: 718-724.
29. Morrison DJ, English MA, Licht JD: WT1 induces apoptosis through transcriptional regulation of the proapoptotic Bcl-2 family member Bak. Cancer Res 2005; 65: 8174-8182.
30. Bossi G, Sacchi A: Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. Head Neck 2007; 29: 272-284.
31. Okamoto T, Izumi H, Imamura T, Takano H, Ise T, Uchiumi T, Kuwano M, Kohno K: Direct interaction of p53 with the Y-box binding protein, YB-1: a mechanism for regulation of human gene expression. Oncogene 2000; 19: 6194-6202.
32. Magrini R, Bhonde MR, Hanski ML, Notter M, Scherubl H, Boland CR, Zeitz M, Hanski C: Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status. Int J Cancer 2002; 101: 23-31.
33. Motwani M, Jung C, Sirotnak FM, She Y, Shah MA, Gonen M, Schwartz GK: Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts. Clin Cancer Res 2001; 7: 4209-4219.
34. Jung JJ, Jeung HC, Lee JO, Kim TS, Chung HC, Rha SY: Putative chemosensitivity predictive genes in colorectal cancer cell lines for anticancer agents. Oncol Rep 2007; 18: 593-599.